ClinicalThought

Share

Program Content

Activities

  • CDK4,6 Inhibitors in Breast Cancer
    Experts Answer Your Questions on CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 05, 2024

    Expires: July 04, 2025

  • Inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
    Des experts répondent à vos questions concernant les inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 09, 2024

    Expires: August 08, 2025

  • Inibidores de CDK4/6 no câncer de mama HR+/HER2-
    Especialistas respondem às suas perguntas sobre inibidores de CDK4/6 no câncer de mama HR+/HER2-
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 19, 2024

    Expires: August 18, 2025

  • Los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
    Los expertos responden a sus preguntas sobre los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 21, 2024

    Expires: August 20, 2025

Faculty

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation